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Background: Flu-like symptoms (FLS) are common side effects of interferon beta (IFN-β) treatment in patients with
Multiple Sclerosis (PwMS) and are associated with post-injection cytokine surge. We hypothesized that vitamin D3
supplementation would ameliorate FLS by decreasing related serum cytokines’ levels.
Methods: In a randomized, double blind study of 45 IFNβ-treated PwMS, 21 patients were assigned to 800 IU of
vitamin D3 per day (low dose), while 24 patients received 4,370 IU per day (high dose) for one year. FLS were
assessed monthly by telephonic interviews. Serum levels of 25-hydroxy-D (25-OH-D), calcium, PTH, IL-17, IL-10 and
IFN-γ were measured periodically. EDSS, relapses, adverse events and quality of life (QoL) were documented.
Results: 25-OH-D levels increased to a significantly higher levels and PTH levels decreased in the high dose group.
There was no significant change in FLS. IL-17 levels were significantly increased in the low dose group, while
patients receiving high dose vitamin D had a heterogeneous IL-17 response. No significant differences in relapse
rate, EDSS, QoL, serum IL-10 and IFNγ were found. Hypercalcemia or other potential major adverse events were not
observed.
Conclusion: Vitamin D supplementation to IFN−β treated PwMS, at the doses used, seems safe and associated
with dose-dependent changes in IL-17 serum levels, while not affecting IFN−β related FLS.
Trial registration: ClinicalTrials.gov ID: NCT01005095
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Flu-like symptoms (FLS) are well known side-effects of
interferon beta (IFN-β) treatment for patients with Mul-
tiple Sclerosis (PwMS). Over half of the treated patients
experience systemic adverse-effects after treatment initi-
ation [1]. Although these symptoms tend to diminish with
time, some patients experience ongoing FLS and are* Correspondence: milleras@netvision.net.il
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reproduction in any medium, provided the orunable to tolerate the drug. FLS are often the reason for
inadequate adherence to medication and for treatment
discontinuation, which may reach beyond 20% of those
who stopped using IFN-β due to adverse effects [2].
FLS have been shown to be related to a post IFN-β in-
jection surge of cytokines, such as IL-6, TRAIL and IP-
10/CXCL2 by peripheral blood mononuclear cells [3,4].
The accumulating evidences that vitamin D may down
regulate the secretion of these cytokines [5-7], led us to
hypothesize that vitamin D supplementation may ameli-
orate IFN-β-induced FLS.td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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MS treatment is yet to be determined. Recently, an ob-
servational study of MS patients suggested that serum
25-hydroxy-vitamin D (25-OH-D) level was associated
with a reduced relapse risk only among patients treated
with IFN-β [8], while in another patient cohort no asso-
ciation between 25-OH-D and disease activity was
detected among IFN-β -treated MS patients [9]. We have
lately reported that high dose vitamin D supplementation
is associated with decreased melatonin secretion in IFN-β
treated PwMS [10], implying that melatonin may be one
of the mediators of 25-OH-D action on the immune sys-
tem. Levels of melatonin as well as of other mediators
may potentially explain some of the variation in the clin-
ical and immunological response to vitamin D.
Furthermore, a clinical trial of vitamin D3 as an add-
on to IFN-β treatment in MS patients demonstrated a
reduction in MRI disease activity compared to a placebo
group [11]. However this effect has yet to be replicated
in larger cohorts.
The primary objective of the present study was to test
whether vitamin D supplementation may ameliorate
IFN-β-induced FLS. Secondary objectives were to evalu-
ate the safety and tolerability of vitamin D in two differ-
ent regimens, to determine the extent it influences
serum 25-OH-D and PTH levels and to assess the effect
of vitamin D supplementation on IFN-β- treatment effi-
cacy, determined by relapse rate and EDSS, as well as on
the serum levels of cytokines associated with immune-
mediated diseases such: IL17, IFNγ and IL-10, proposed




Patients with clinically and laboratory definite Relapsing
Remitting MS according to the revised McDonald’s cri-
teria [14], who attended our clinic at the MS Center at
Carmel Medical Center, Haifa for routine follow-up from
November 2010 to March 2011 were offered to partici-
pate (n = 49). The study was approved by the local
Helsinki Ethics Committee of Carmel Medical Center, and
all participants gave their written informed consent. The
trial was registered at ClinicalTrials.gov ID: NCT01005095.
Inclusion Criteria were: Age ≥ 18 years ; assigned to
initiate IFN-β treatment (n = 1) or patients who contin-
ued to suffer from FLS beyond 4 months of treatment
with IFN-β (n = 44); 25-OH-D blood levels < 75 nmol/l
and EDSS score < 7. Exclusion Criteria consisted of
abnormalities of vitamin D related hormonal system
other than low dietary intake or decreased sun exposure
(such as: intestinal malabsorption, chirosis, nephrotic syn-
drome, hyperthyroidism, creatinine clearance of less than
40 ml/min, rickets, hypoparathyroidism, hypercalcemia atbaseline, known malignancy, Granulomatous disorders
and lymphomas). We also excluded patients who took
medications that influence vitamin D metabolism, namely,
Orlistat, anticonvulsants, Rifampin, Isoniazide, Ketocona-
zole, 5FU and Leucovorin. Patients with conditions of in-
creased susceptibility to hypercalcemia were excluded too:
known arrhythmia, heart disease, nephrolithiasis and
treatment with Digitalis or Hydrochlorothiazide. Pregnant
women were not included.
Participation after enrolment was terminated in case
of withdrawal of IFN-β treatment for any reason, preg-
nancy, hypercalcemia or patient’s decision.
Study groups, randomization and supplementation
regimens
The study included two interventional groups: a “high
dose” group assigned to oral treatment of one bottle
containing 75,000 IU of vitamin D3 solution every
3 weeks in addition to 800 IU of vitamin D3 by daily
tablets (total of 4370 IU/d); and a “low dose” group re-
ceiving one bottle of placebo solution every 3 weeks be-
sides 800 IU of vitamin D3 by daily tablets (total of
800 IU/d). The vitamin D content in solution bottles
and tablets was quantitatively evaluated by the manufac-
turers and the results were within the specification. The
assignment to groups was randomly set in advance,
according to recruitment order. Vitamin D supplementa-
tion was double-blind in this study – both participants,
treating physician and investigators were unaware of the
ingredients of the solution bottles.
After recruitment, patients were required to adhere to
study vitamin D products and to refrain from taking any
other vitamin D formulations. The half-life of 25-OH-D
is about 2–3 weeks [15]. Basic pharmacology suggests
that after a period of 5 half-lives, serum levels are at a
new steady state [16]. Therefore, by 3 months from en-
rolment, serum 25-OH-D levels represent the new
steady state equilibrium, and are not influenced by pre
study vitamin D intake.
Clinical follow-up
FLS were assessed by phone interviews at least once per
month, and if participants were available, twice monthly.
Patients were asked to refer to their last IFN injection
and to rate the extent of FLS on a Likert scale. A score
from 0 (not at all) to 5 (very strong), was given to each
FLS component: myalgia, chills, headache, malaise and
fatigue, exacerbation of neurologic symptoms, sweating
and difficulty to function compared to the time before
injection. The scores of individual components were
summed, yielding a total FLS score ranging from 0 to 35
[3,4]. If a patient was interviewed twice at a given
month, the higher score was used for analysis, in order
to be sure that worst possible symptoms are recorded
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Patients were allowed to use pain relieving medications
during the study. Information about the use of these medi-
cations over 6 months was obtained in the interviews.
Complete neurologic examination and EDSS scoring
were done at baseline, after 6 months and at 1 year. Re-
lapses were recorded throughout the study. When new
MS symptoms were reported in the phone interview, the
patient was invited to further evaluation at the clinic.
Relapses were defined as new neurologic deficits, lasting
longer than 24 hours, with no evidence of an infection
[14]. All relapses were confirmed by objective neurologic
examination.
Health related quality of life (HRQoL) was evaluated
at baseline and at the completion of the study, using the
‘Functional assessment of MS’ questionnaire (FAMS),
which is divided to six subscales: mobility, symptoms,
emotional well-being (depression), general contentment,
thinking/fatigue, and family/social well-being [17]. The
total FAMS score is calculated by summing all subscale
scores, ranging from 0 to 232. High score denotes de-
creased QoL.
At each clinic visit during the trial patients were asked
to report any new adverse event that might have been
somehow related to vitamin supplementation.
Laboratory evaluation
Blood samples were collected at baseline and after 3, 6,
and 12 month of vitamin D supplementation, processed
for serum within 45 minutes from its withdrawal and
stored at −80°C until analysis. Serum 25-OH-D and cal-
cium levels were measured at baseline, 3, 6 and 12 month,
while serum PTH measured at baseline and 3 months.
Vitamin D total assay uses chemiluminescent immuno-
assay (CLIA) technology and was tested on the Liaison
analyzer (DiaSorin S.p.A., Italy) for the quantitative deter-
mination of 25-hydroxy-vitamin D.
PTH assay uses chemiluminescent immunoassay
(CLIA) technology and was tested on the Immulite 2000
analyzer (Siemens AG) for intact Parathyroid hormone
quantitative measurement.
Serum cytokine levels (IL10, IFNγ and IL17) were
measured at baseline and after 3 months. Commercial
ELISA kits were used: IL-10 (Quantikine HS, R&D sys-
tems, USA), IFNγ (eBioscience, USA) and IL-17 (Enzo
Life sciences, USA). Cytokine concentrations were deter-
mined as described by the manufacturers’ user manual.
All measurements from each patient were performed in
the same plate in the same assay. Intra-assay coefficient
of variations (CV) was ≤ 10% for each plate.
Statistical analysis
Data analysis was performed using the SPSS statistical
package (SPSS Inc., Chicago, IL, ‘USA). Comparisons ofpatients’ characteristics between study groups at baseline
were done by Student’s t-test or Mann–Whitney test,
according to data distribution. Changes in 25-OH-D
levels, calcium and EDSS were analyzed by ANOVA with
repeated measures. PTH and IL-17 levels as well as
FAMS scores at baseline and after 3 months were com-
pared by paired Student’s t-test. Alterations in IFN-γ
levels were analyzed by Wilcoxon Signed Rank test.
Comparisons of FLS scores at various times were done
by mixed model ANOVA. This procedure takes into ac-
count the intra-correlation of repeated measurements
carried out at the same subject and does not exclude
subjects with incomplete data at follow-up. FLS scores
according to the use of pain relieving medications were
compared by Mann–Whitney test. Comparisons be-
tween proportions of participants who had a relapse
were done by Chi square test. Summary statistics are
reported as mean ± Standard deviation and as median
(range).
Annualized relapse rates were calculated as number of
relapses divided by the sum of person-years under
follow-up. 95% Confidence intervals were calculated
using normal approximation. Relapse rates were com-
pared by Mid-P exact test, using the Open Epi epidemio-
logic calculator (Atlanta, GA, USA).
According to our initial power analysis, a sample of
100 patients, 50 in each vitamin D dosage group, was
needed to provide 80% power to detect a mean change
in the FLS score of 1 point, using t-tests for unpaired
values, alpha 0.05, standard deviation 1.5 points. After
45% intended enrollment and 1 year of follow up, an in-
terim analysis of the data was conducted and the prob-
ability of finding a significant difference in FLS scores at
study end, assuming the trend to date would continue,
was calculated with the intent to close enrollment, if the
probability decreased below 50%.
Results
Flow chart of the study is shown in Figure 1. Patients’
characteristics at recruitment are provided in Table 1.
All participants, except one patient, were lengthy treated
with IFN-β, and were experiencing FLS despite continu-
ous use of IFN-β for more than 4 months.
Serum vitamin D, PTH and calcium levels
Serum 25-OH-D levels at baseline, 3 months, 6 months
and 1 year in the two dosage regimens are presented in
Figure 2. After 3 months of supplementation, 25-OH-D
levels significantly increased from 48 ± 14.2 to 68 ±
11 nmol/l and from 48.2 ± 13.9 to 122.6 ± 32 nmol/l in
the low and high dose groups, respectively. The high
dose supplementation resulted in significantly higher
serum 25-OH-D levels compared to low dose through-
out the follow up (P < 0.001). While in the high dose
Figure 1 Study flow chart.







800 IU/d 4,370 IU/d
N = 21 N = 24
Age (years) 44.7 ± 10.7 43.1 ± 12.3 0.7 b
43.6 (26.7-63.9) 43.1 (21.7-63.7)
Gender (Male/Female) F 13 (62%) F 19 (79%) 0.2 c
M 8 (38%) M 5 (21%)
Time from MS diagnosis
(years)
9.3 ± 7.4 6 ± 5.7 0.08 d
8.1 (0.4-32.9) 3.4 (0.3-19.1)
IFN-β treatment duration
(months)
61.3 ± 46 38.9 ± 32.5 0.1 d
59.1 (3.1-144.1) 23.4 (1.2-96.7)
EDSS 3.6 ± 2.2 2.9 ± 2.0 0.4 d
4.5 (0–7) 2.5 (0–7)
Patients with relapses during
the year preceding
randomization
6/21 (28.6%) 8/24 (33.3%) 0.7 c
Annualized relapse rate
during the year preceding
randomization
0.38 ± 0.26 0.28 ± 0.23 0.6 e
a. Summary statistics are mean ± standard deviation and median (range).
b. Student’s t-test.
c. Chi square test.
d. Mann–Whitney test.
e. Mid-P exact test.
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at all time points (P ≤ 0.01), in the low dose group a sig-
nificant increase was found only after 3 months (P =
0.006) and 6 months (P = 0.04), whereas 25-OH-D levels
were not significantly different from baseline by the end
of 12 month of follow up.
PTH decreased in the high dose group, while it did
not significantly change with low dose vitamin D
(Table 2). Serum calcium levels remained stable and
within normal range in both dosage groups, throughout
the study (Table 2).
Flu-like symptoms
FLS scores of the patients are shown in Figure 3. No sig-
nificant change in FLS severity was noted. Comparisons
of FLS scores between patients who received high and
low doses of vitamin D indicated insignificant differ-
ences at all time points.
The majority of participants (68%-79% depending on
month) opted to use pain relieving medications, namely
Ibuprofen, Paracetamol or Dipyrone. As could be expected,
mean FLS scores were higher in participants who needed
analgesics, but the differences did not reach statisticalsignificance, regardless of vitamin D dose (Figure 4). Not-
ably, most patients were using analgesics on a regular and
frequent basis, therefore FLS data without pain relieving
medications came from different patients at different time
points.
An interim data analysis was conducted and the data
were reviewed for futility. At 45% enrollment, the condi-
tional power of detecting a difference in FLS given the
current trend was calculated to be below 5%. That is to
say, there was less than 5% probability to find a signifi-
cant difference in FLS between the groups, if the study
would continue to the planned number of recruitments.
Consequently, the trial was closed to further enrollment.
MS clinical parameters
Clinical parameters are presented in Table 2. No signifi-
cant changes in FAMS score, EDSS or relapse rates were
noted in either group. The statistically insignificant in-
creased relapse rate in the high dose group stemmed
from one patient who had 3 relapses after enrolment
compared to none at the year prior randomization.
Serum cytokines
Cytokine levels are shown in Table 2. Serum IL-17 mea-
surements were available at baseline and after 3 months of
vitamin D supplementation for 18 patients in the low dose
group and for 20 patients in the high dose group (Figure 5).
3 patients in each dosage group had IL-17 levels below the
detection threshold of the ELISA kit at both time points
Figure 3 Flu like symptoms score by time from enrollment to
vitamin D supplementation. FLS were assessed by monthly phone
interviews. Patients rated the extent of FLS on a Likert scale
(a total FLS score ranging from 0 to 35). No significant change in
FLS severity was noted in both dosage groups.
Figure 2 25-OH- vitamin D serum levels. Serum 25-OH-D
(25-hydroxy-vitamin D) was measured at baseline, 3, 6 and
12 month using a chemiluminescent immunoassay. The high dose
supplementation resulted in significantly higher serum 25-OH-D
levels compared to low dose throughout the follow up (P < 0.001).
With high dose, 25-OH-D levels were significantly above baseline at
all time points (P≤ 0.01), while low dose resulted in significantly
increased 25-OH-D levels compared to baseline only at 3 months
(P = 0.006) and at 6 months (P = 0.04).
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as zero for data averaging in Table 2). A significant in-
crease from 4.01 ± 3.99 to 9.14 ± 9.9 pg/ml in serum IL-17
was detected at 3 month in the low dose vitamin D group
(p = 0.037). Serum IL-17 response to high dose vitamin D
was non homogenous. While 8 patients (40%) had de-
creased serum IL-17 levels after 3 months, 9 patients
(45%) had increased IL-17 levels after the same period of
high dose supplementation. The other 3 patients (15%)
had IL-17 levels below the detection threshold at both
time points. We are not aware of any convincing scientific
data that indicate which magnitude of serum IL-17 change
is deemed clinically meaningful. Therefore, an increase in
IL-17 serum levels was defined as a positive change, while
a decrease was defined as negative change, regardless of
magnitude (Figure 5).
Non significant changes were found in IL-10 and IFN-γ
levels (Table 2).
Adverse events
There was no occurrence of hypercalcemia and no re-
ports on new adverse event which could be vitamin Dsupplement related. None of the patients stopped par-
ticipation due to adverse events.
Discussion
The role of vitamin D in MS pathogenesis is currently at
the focus of multidisciplinary research initiatives. Prior
research evaluated the role of vitamin D deficiency as a
risk factor for development of MS and as a modifier of
its clinical course [18] as well as of common symptoms
of PwMS, such as pain and depression [19,20]. The
interaction between IFN-β and vitamin D in terms of
their combined efficacy was also previously studied both
clinically [8,9,11] and in an animal model [21], with yet
conflicting results.
In the current work we focused on a different aspect
of the vitamin D – IFN-β interaction, namely: the effect
on FLS, a bothering, sometimes debilitating, adverse-
effect of IFN-β treatment. We hypothesized that vitamin
D may ameliorate these symptoms, by modulating a
post-injection cytokine surge. In the present random-
ized, double-blind study, vitamin D supplementation did
not affect IFN-β-induced FLS. Futility analysis showed
that this conclusion was unlikely to change with recruit-
ment of more patients.
The desired 25-OH-D level for the general population
is derived from epidemiologic studies of the relationship
between this level and the risk for osteoporosis. The
controversy in translating the data to practice is reflected
in conflicting recommendations of current guidelines.
While the American institution of medicine recommends
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crinology defines levels below 75 nmol/l as insufficient
and below 50 nmol/l as deficient [23]. Additionally, since
some findings suggest that high dose of vitamin D might
have a direct toxic effect [24], the optimal level range for
vitamin D has not yet reached consensus.
Our data show that the high dosage regimen is more
effective in achieving 25-OH-D serum level above
75 nmol/l in MS patients. After 6 months, only 25% of
the low dose vitamin D group reached serum levels of
75nmo/l or higher, compared to 100% of the high dose
group. By the end of the study only 13% of those treated
with 800 IU/d compared to 60% of those treated with
4,370 IU/d reached the 75 nmo/l target.
Our patients’ average EDSS score was about 3.5, imply-
ing that most of them were not housebound and could
have been influenced by outdoor sun exposure. Therefore,
the observed decline in 25-OH-D from 6 months to
12 months in both groups can be partly attributed to win-
ter conditions at the 12 month visit. Annual variation in
25-OH-D levels, with decreased levels at winter, has previ-
ously been reported in Israel [25]. All patients confirmedTable 2 Clinical and Laboratory results a
Study group Low dose group
800 IU/day
Parameter Baseline 3Months 6 Months End
Annual Relapse rate 0.38±0.26 – – 0.34±0.
EDSS 3.6±2.2 – 3.6±2.1 3.6±2.
4.5 2.8 3.0
(0-7) (0-7) (0-7)
Quality of life score (FAMS) 145.6±30.8 – – 142.7±3
138 134
(103-205) (94-21
Serum calcium (mg/dl) 9.5±0.4 9.7±0.3 9.5±0.4 9.5±0.
9.5 9.6 9.5 9.4
(8.7-10.2) (9.2-10.2) (9-10.3) (8.9-10
PTH (pg/ml) 36.7 ±17.1 31.6±11.5 – –
35.5 29.4
(11.5-77.4) (12.8-53.3)
IFN-γ (pg/ml) 0.20±0.22 0.14±0.2 – –
0.08 0.03
(0-0.61) (0-0.77)
IL17 (pg/ml) 4.01±3.99 9.14±9.9 – –
3.74 7.8
(0-11) (0-38.3)
IL10 (pg/ml) undetected undetected – –
a. Summary statistics are mean ± standard deviation and median (range).
b. Mid-P exact test.
c. ANOVA with repeated measures.
d. Paired Student’s t-test.their adherence to the study regimen in every phone con-
versation as well as in each clinic visit. However, attrition
in compliance can’t be ruled out and might have contrib-
uted to the decreased 25-OH-D levels after 12 months in
both dosage groups.
As of today, only few, small scale randomized con-
trolled trials of vitamin D supplementation have been
completed, and with conflicting results. Burton et al.
[26] randomized 49 MS patient to no supplementation
or escalating vitamin D doses up to 40,000 IU/day over
28 weeks followed by 10,000 IU/day for 12 weeks,
thence down-titrated to 0 IU/d until the end of 52 weeks
of follow up. Treatment group patients appeared to have
fewer relapses and a persistent reduction in T-cell prolif-
eration compared to controls. In another study, 23 pa-
tients were randomized to 6000 IU/d vitamin D or
placebo. After 6 months follow up no significant differ-
ences were detected in various MRI endpoints, and there
were more relapses in the high dose group [27].
Recently, Soilu-Hanninen et al. [11] reported a 1 year,
double blind, placebo controlled, randomized study in
66 MS patients with vitamin D3 as an add-on treatmentHigh dose group
4370 IU/day
p-value Baseline 3Months 6 Months End p-value
27 0.88 b 0.28±0.23 – – 0.51±0.34 0.32 b
3 0.1c 2.9±2.0 – 3.4±2.3 3.3±2.4 0.26 c
2.5 3 2.5
(0-7) (0-7) (0-7)
2.5 0.68 d 147.9±38.6 – – 146.6±45.5 0.84 d
158 150
2) (85-211) (71-225)
5 0.4 c 9.6±0.3 9.7±0.2 9.6±0.2 9.4±0.5 0.2 c
9.5 9.5 9.6 9.4
.3) (9.2-10.1) (9.4-10.1) (9.2-10.1) (8.6-10.1)
0.17 d 30.4±13.5 25.0±10.0 – – 0.04 d
31.1 21.7
(8.3-49.9) (6.4-41.4)
0.13 d 0.51±1.1 0.58±1.3 – – 0.7 d
0.05 0.07
(0-4.4) (0-5.8)
0.04 d 5.83±6.1 6.38±6.7 – – 0.75 d
4.3 3.4
(0-19) (0-20.8)
– undetected undetected – – –
Figure 5 Changes in IL-17 serum levels after 3 months
supplementation with vitamin D. A significant increase in serum
IL-17 was detected at 3 month in the low dose vitamin D group
(p = 0.037). Serum IL-17 response to high dose vitamin D was
heterogeneous. 3 patients in each dosage group had IL-17 levels
below the detection threshold of the ELISA kit at both time points
(not shown in the figure).
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proved MRI outcomes, with no significant differences in
clinical outcomes. Similarly, a 96-week randomized con-
trolled trial of 68 patients found that supplementation
with 20,000 IU vitamin D(3) weekly did not result in
beneficial effects on clinical MS-related outcomes [28].
The present study is akin to prior trials in duration
and sample size. We found no trend of clinical improve-
ment regarding disease activity in PwMS after vitamin D
supplementation; however MRI outcomes were not in-
cluded in this study. Since patients participating in our
study were all but one under long-term IFN-β treatment,
disease activity as assessed by relapse rate, relapse num-
bers and EDSS change was as expected relatively low.
The study was therefore underpowered to assess the ef-
fect of vitamin D on MS activity, and larger scale trials
and meta-analysis of available data, including MRI pa-
rameters, are needed to clarify the benefit of vitamin D
on MS disease activity and/or its symptoms.
IL-17 is a pro-inflammatory cytokine produced by Th-
17 cells, and has been advocated to play a role in MS
pathogenesis [29]. IL-17 has been found to be highly
expressed in MS lesions, and Th17 cells are abundant in
active MS lesions [30]. Vitamin D has been shown to de-
crease Th-17 cell activity in animal models of MS
[31,32], and to down regulate IL-17 production in Th17
cells isolated from MS patients [33]. IFN-β was also
shown to inhibit Th17 cell development, and this effect
is considered to be one of the mechanisms of actions of
IFN-β in the treatment of MS [34].
Since both vitamin D and IFN-β have been shown to
down regulate IL-17 production, we premised thatFigure 4 Flu like symptoms score and use of pain relieving
medications. No statistically significant differences were found in
FLS scores between patients who used analgesics and patients who
did not use analgesics, regardless of vitamin D dose.vitamin D supplementation would decrease IL-17 serum
levels in our IFN-β treated patients. Unexpectedly, a sig-
nificant increase in serum IL-17 was found in the low
dose group of this study, while non-homogenous trends
in IL-17 levels were noted in the high dose group. Due
to ethical considerations, this study did not include a
pure placebo group, without any kind of vitamin D sup-
plementation. Therefore, it is impossible to determine
from this data, whether the demonstrated increased
IL17 was due to the low dose supplementation, or the
consequence of some other unrecognized confounder.
Since accumulating data point towards both vitamin D
and IFN-β as inhibitors of Th17, it’s more probable that
the increased IL-17 in the low dose group in this study
was not due to vitamin D. Notably, baseline measure-
ments were carried out at winter while 3 months tests
were done during spring. Seasonal variation in immune
cell subsets and cytokines has been previously described,
and could have contributed to the variation in serum cy-
tokines in this study [35,36].
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creasing proportion of patients on higher pharmacological
doses of vitamin D is in agreement with earlier studies
which demonstrated that high dose vitamin D decreases
Th-17 cell activity in animal models of MS [31,32] as well
as in PwMS [33]. Beneficial effects of vitamin D increase
may be undetectable in IFN-β treated patients, because of
the strong immunomodulatory effect of this cytokine [9],
however our results indicate that the add on of large doses
of vit D could be beneficial. The question remains whether
further increasing vitamin D dose, above 4,370 IU per day,
would entail significant IL17 down-regulation in a greater
proportion of MS patients.
Furthermore, IL-17 data must be interpreted with cau-
tion as serum IL-17 is not an established biomarker of
MS disease activity. IL17 serum levels before treatment
with IFN−β, as well as 3 months after treatment, could
not be correlated to disease activity parameters in a co-
hort of 118 MS patients [37], and IL‑17 levels showed a
trend towards being higher in MS patients with inactive
disease compared to those with active disease in another
patient cohort of 169 patients [38].
No change in serum levels of other cytokines was
noted in this work, as well as in a previous study [39],
assessing the impact of vit D supplementation.
Notably, PTH levels decreased significantly in the high
dose vitamin D treated group. This change in PTH level
was found also in healthy people after vitamin D supple-
mentation [40]. The role of PTH as a potential immune-
modulator has been debated. Both B and T lymphocytes
express PTH receptors [41].While some studies imply
that PTH may be anti-inflammatory [41] other studies
found that PTH is in fact increased during MS relapse
[42]; still others found no correlation at all between
PTH levels and immune cells function [43]. Neverthe-
less, PTH is a well known stimulator of bone resorption.
Its decrement in our patients who received the high dose
of vitamin D may imply an advantage, though yet to be
confirmed, in terms of bone health and prevention of
osteoporosis, which is particularly common and debili-
tating in PwMS [44].
Conclusions
The present randomized, double-blind, placebo-controlled
trial, though modest in its sample size, did not detect
beneficial effects of vitamin D supplementation on IFN-
β -related FLS in PwMS, but did provide support to its
immunomodulatory properties. Vitamin D appears to in-
fluence IL-17 secretion in IFN-β -treated patients in a dose
dependent manner. While serum IL-17 was significantly in-
creased after low dose vitamin D treatment, heterogeneous
responses were noted after high dose vitamin D.
The findings are in-line with a series of clinical trials of
vitamin D supplementation for PwMS, which generallydid not show added benefit in terms of clinical efficacy,
but did show clues for improvement in markers of inflam-
mation and related MRI findings, beyond the reported ef-
fects on disease prevention [45,46]. Further large scale
trials and meta-analyses of available data are needed to
elucidate the role of vitamin D for immunocompetence
and as part of the treatment armature of immune-
mediated diseases as MS.
Abbreviations
FAMS: ‘Functional assessment of MS’ questionnaire; FLS: Flu-like symptoms;
HRQoL: Health related quality of life; IFN-β: Interferon beta; PwMS: Patients
with multiple sclerosis; QoL: Quality of life; 25-OH-D: 25-Hydroxy-D.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
DG participated in the design of the study, reviewed the literature,
coordinated the study, performed clinical evaluations of the patients,
participated in statistical analysis and wrote the manuscript. BH participated
in the coordination of the study and in clinical evaluations of the patients.
LGM participated in the design and coordination of the study, carried out
the immunoassays and revised the manuscript. ESR participated in the
design of the study, carried out the immunoassays and revised the
manuscript. RO participated in the design of the study and carried out
vitamin D and PTH assays. IL participated in the design of the study and
performed statistical analysis. SD participated in clinical evaluations of the
patients. MB participated in the design of the study. SIS participated in the
design of the study and revised the manuscript. AM conceived the study,
participated in its design, participated in clinical evaluations of the patients
and revised the manuscript. All authors read and approved the final
manuscript.
Acknowledgments
This study was supported by Merck Serono- Israel and Bayer Schering- Israel.
Vitamin D supplements and Placebos were donated by CTS – Israel and
Altman – Israel.
Author details
1Division of Neuroimmunology & Multiple Sclerosis Center, Carmel Medical
Center, 7 Michal Street, Haifa 34362, Israel. 2Department of Neurology,
Carmel Medical Center, Haifa, Israel. 3Central Laboratory of Haifa and Western
Galilee, Clalit Health Services, Haifa, Israel. 4Department of Community
Medicine & Epidemiology, Carmel Medical Center, Haifa, Israel. 5Rappaport
Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
Received: 19 January 2013 Accepted: 31 May 2013
Published: 14 June 2013
References
1. Munschauer FE III, Kinkel RP: Managing side effects of interferon-beta in
patients with relapsing-remitting multiple sclerosis. Clin Ther 1997,
19(5):883–893.
2. O’Rourke KE, Hutchinson M: Stopping beta-interferon therapy in multiple
sclerosis: an analysis of stopping patterns. Mult Scler 2005, 11(1):46–50.
3. Buttmann M, Merzyn C, Rieckmann P: Interferon-beta induces transient
systemic IP-10/CXCL10 chemokine release in patients with multiple
sclerosis. J Neuroimmunol 2004, 156(1–2):195–203.
4. Buttmann M, Merzyn C, Hofstetter HH, Rieckmann P: TRAIL, CXCL10 and
CCL2 plasma levels during long-term Interferon-beta treatment of
patients with multiple sclerosis correlate with flu-like adverse effects but
do not predict therapeutic response. J Neuroimmunol 2007,
190(1–2):170–176.
5. Turk S, Akbulut M, Yildiz A, Gurbilek M, Gonen S, Tombul Z, Yeksan M:
Comparative effect of oral pulse and intravenous calcitriol treatment in
hemodialysis patients: the effect on serum IL-1 and IL-6 levels and bone
mineral density. Nephron 2002, 90(2):188–194.
Golan et al. BMC Neurology 2013, 13:60 Page 9 of 10
http://www.biomedcentral.com/1471-2377/13/606. Müller K, Haahr PM, Diamant M, Rieneck K, Kharazmi A, Bendtzen K:
1,25-Dihydroxyvitamin D3 inhibits cytokine production by human blood
monocytes at the post-transcriptional level. Cytokine 1992, 4(6):506–512.
7. Zhang X, Li P, Bao J, Nicosia SV, Wang H, Enkemann SA, Bai W: Suppression
of death receptor-mediated apoptosis by 1,25-dihydroxyvitamin D3
revealed by microarray analysis. J Biol Chem 2005, 280(42):35458–35468.
8. Stewart N, Simpson S, van der Mei I, Ponsonby A-L, Blizzard L, Dwyer T,
Pittas F, Eyles D, Ko P, Taylor BV: Interferon-β and serum
25-hydroxyvitamin D interact to modulate relapse risk in MS. Neurology
2012, 79(3):254–260.
9. Løken-Amsrud KI, Holmøy T, Bakke SJ, Beiske AG, Bjerve KS, Bjørnarå BT,
Hovdal H, Lilleås F, Midgard R, Pedersen T, Benth JS, Sandvik L, Torkildsen O,
Wergeland S, Myhr KM: Vitamin D and disease activity in multiple
sclerosis before and during interferon β treatment. Neurology 2012,
79(3):267–273.
10. Golan D, Staun-Ram E, Glass-Marmor L, Lavi I, Rosenberg O, Dishon S, Barak
M, Ish-Shalom S, Miller A: The influence of vitamin D supplementation on
melatonin status in patients with multiple sclerosis. Brain Behav Immun
2013. In press. [http://dx.doi.org/10.1016/j.bbi.2013.04.010].
11. Soilu-Hänninen M, Åivo J, Lindström BM, Elovaara I, Sumelahti ML, Färkkilä
M, Tienari P, Atula S, Sarasoja T, Herrala L, et al: A randomised, double
blind, placebo controlled trial with vitamin D3 as an add on treatment
to interferon beta-1b in patients with multiple sclerosis. J Neurol
Neurosurg Psychiatry 2012, 83(5):565–571.
12. Weber MS, Hemmer B: Cooperation of B Cells and T Cells in the
pathogenesis of Multiple Sclerosis. In Molecular Basis of Multiple Sclerosis.
Volume 51. Edited by Martin R, Lutterotti A. Heidelberg: Springer;
2010:115–126.
13. Kiedorf K, Wang Y, Neumann H: Immune-Mediated CNS damage. In
Molecular Basis of Multiple Sclerosis. Volume 51. Edited by Martin R,
Lutterotti A. Heidelberg: Springer; 2010:173–196.
14. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara
K, Havrdova E, Hutchinson M, Kappos L, et al: Diagnostic criteria for
multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol
2011, 69(2):292–302.
15. Bringhurst FR DM, Kronenberg HM: Hormones and disorders of mineral
metabolism. In Williams textbook of endocrinology. 11th edition. Edited by
Kronenberg HM, Melmed S, Polonsky KS, Larsen PR. Philadelphia, PA:
Saunders Elsevier; 2008:1217–1218.
16. Buxton I: Pharmacokinetics and pharmacodynamics: the dynamics of
drug absorption, distribution, action, and elimination. In Goodman &
Gilman’s the pharmacological basis of therapeutics. 11th edition. Edited
by Brunton LL. New York: McGraw-Hill Medical Publishing Division;
2006:1–41.
17. Cella DF, Dineen K, Arnason B, Reder A, Webster KA, Karabatsos G, Chang
C, Lloyd S, Steward J, Stefoski D: Validation of the functional assessment
of multiple sclerosis quality of life instrument. Neurology 1996,
47(1):129–139.
18. Ascherio A, Munger KL, Simon KC: Vitamin D and multiple sclerosis. Lancet
Neurol 2010, 9(6):599–612.
19. Knippenberg S, Bol Y, Damoiseaux J, Hupperts R, Smolders J: Vitamin D
status in patients with MS is negatively correlated with depression, but
not with fatigue. Acta Neurol Scand 2011, 124(3):171–175.
20. Straube S, Andrew Moore R, Derry S, McQuay HJ: Vitamin D and chronic
pain. Pain 2009, 141(1–2):10–13.
21. van Etten E, Gysemans C, Branisteanu DD, Verstuyf A, Bouillon R, Overbergh
L, Mathieu C: Novel insights in the immune function of the vitamin D
system: synergism with interferon-beta. J Steroid Biochem Mol Biol 2007,
103(3–5):546–551.
22. Institute of Medicine: Dietary Reference Intakes for Calcium and Vitamin D.
Washington, DC: The National Academies Press; 2011.
23. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA,
Heaney RP, Murad MH, Weaver CM: Evaluation, treatment, and prevention
of vitamin D deficiency: an endocrine society clinical practice guideline.
J Clin Endocrinol Metab 2011, 96:1911–1930.
24. Sanders KM, Stuart AL, Williamson EJ, Simpson JA, Kotowicz MA, Young D,
Nicholson GC: Annual high-dose oral vitamin D and falls and fractures in
older women: a randomized controlled trial. JAMA 2010,
303(18):1815–1822.
25. Saliba W, Rennert HS, Kershenbaum A, Rennert G: Serum 25(OH)D
concentrations in sunny Israel. Osteoporos Int 2012, 23(2):687–694.26. Burton JM, Kimball S, Vieth R, Bar-Or A, Dosch HM, Cheung R, Gagne D,
D’Souza C, Ursell M, O’Connor P: A phase I/II dose-escalation trial of
vitamin D3 and calcium in multiple sclerosis. Neurology 2010,
74(23):1852–1859.
27. Stein MS, Liu Y, Gray OM, Baker JE, Kolbe SC, Ditchfield MR, Egan GF,
Mitchell PJ, Harrison LC, Butzkueven H, et al: A randomized trial of high-
dose vitamin D2 in relapsing-remitting multiple sclerosis. Neurology 2011,
77(17):1611–1618.
28. Kampman MT, Steffensen LH, Mellgren SI, Jørgensen L: Effect of vitamin D3
supplementation on relapses, disease progression, and measures of function
in persons with multiple sclerosis: exploratory outcomes from a double-blind
randomised controlled trial. Mult Scler 2012, 18(8):1144–1151.
29. Korn TMM, Kuchroo VK: Immunological Basis for the Development of
Tissue Inflammation and Organ-Specific Autoimmunity in Animal Models
of Multiple Sclerosis. In Molecular Basis of Multiple Sclerosis. 1st edition.
Edited by Martin R, Lutterotti A. Hamburg: Springer; 2009:51–57.
30. Tzartos JS, Friese MA, Craner MJ, Palace J, Newcombe J, Esiri MM, Fugger L:
Interleukin-17 production in central nervous system-infiltrating T cells
and glial cells is associated with active disease in multiple sclerosis.
Am J Pathol 2008, 172(1):146–155.
31. Chang SH, Chung Y, Dong C: Vitamin D suppresses Th17 cytokine
production by inducing C/EBP homologous protein (CHOP) expression.
J Biol Chem 2010, 285(50):38751–38755.
32. Joshi S, Pantalena LC, Liu XK, Gaffen SL, Liu H, Rohowsky-Kochan C,
Ichiyama K, Yoshimura A, Steinman L, Christakos S, et al:
1,25-dihydroxyvitamin D(3) ameliorates Th17 autoimmunity via
transcriptional modulation of interleukin-17A. Mol Cell Biol 2011,
31(17):3653–3669.
33. Correale J, Ysrraelit MC, Gaitan MI: Immunomodulatory effects of Vitamin
D in multiple sclerosis. Brain 2009, 132(Pt 5):1146–1160.
34. Hong J, Hutton GJ: Regulatory effects of interferon-beta on osteopontin and
interleukin-17 expression in multiple sclerosis. J Interferon Cytokine Res 2010,
30(10):751–757.
35. Maes M, Stevens W, Scharpe S, Bosmans E, De Meyer F, D’Hondt P,
Peeters D, Thompson P, Cosyns P, De Clerck L, et al: Seasonal variation in
peripheral blood leukocyte subsets and in serum interleukin-6, and
soluble interleukin-2 and −6 receptor concentrations in normal
volunteers. Experientia 1994, 50(9):821–829.
36. Killestein J, Rep MH, Meilof JF, Ader HJ, Uitdehaag BM, Barkhof F,
van Lier RA, Polman CH: Seasonal variation in immune measurements
and MRI markers of disease activity in MS. Neurology 2002,
58(7):1077–1080.
37. Bushnell SE, Zhao Z, Stebbins CC, Cadavid D, Buko AM, Whalley ET, Davis JA,
Versage EM, Richert JR, Axtell RC, et al: Serum IL-17F does not predict poor
response to IM IFNbeta-1a in relapsing-remitting MS. Neurology 2012,
79(6):531–537.
38. Kallaur AP, Oliveira SR, Colado Simao AN, de Almeida ER D, Kaminami
Morimoto H, Lopes J, de Carvalho Jennings Pereira WL, Marques Andrade R,
Muliterno Pelegrino L, Donizete Borelli S, et al: Cytokine profile in relapsing
remitting multiple sclerosis patients and the association between
progression and activity of the disease. Mol Med Rep 2013,
7(3):1010–1020.
39. Mahon BD, Gordon SA, Cruz J, Cosman F, Cantorna MT: Cytokine profile in
patients with multiple sclerosis following vitamin D supplementation.
J Neuroimmunol 2003, 134(1–2):128–132.
40. Vieth R, Kimball S, Hu A, Walfish PG: Randomized comparison of the
effects of the vitamin D3 adequate intake versus 100 mcg (4000 IU) per
day on biochemical responses and the wellbeing of patients.
Nutr J 2004, 3:8.
41. Geara AS, Castellanos MR, Bassil C, Schuller-Levis G, Park E, Smith M,
Goldman M, Elsayegh S: Effects of parathyroid hormone on immune
function. Clin Dev Immunol 2010, 2010:1–10.
42. Soilu-Hänninen M, Laaksonen M, Laitinen I, Erälinna J-P, Lilius E-M,
Mononen I: A longitudinal study of serum 25-hydroxyvitamin D and
intact parathyroid hormone levels indicate the importance of vitamin D
and calcium homeostasis regulation in multiple sclerosis. J Neurol
Neurosurg Psychiatry 2008, 79(2):152–157.
43. Smolders J, Menheere P, Thewissen M, Peelen E, Tervaert JW, Hupperts R,
Damoiseaux J: Regulatory T cell function correlates with serum
25-hydroxyvitamin D, but not with 1,25-dihydroxyvitamin D,
parathyroid hormone and calcium levels in patients with relapsing
Golan et al. BMC Neurology 2013, 13:60 Page 10 of 10
http://www.biomedcentral.com/1471-2377/13/60remitting multiple sclerosis. J Steroid Biochem Mol Biol 2010,
121(1–2):243–246.
44. Dobson R, Ramagopalan S, Giovannoni G: Bone health and multiple
sclerosis. Mult Scler 2012, 18(11):1522–1528.
45. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A:
Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis.
JAMA 2006, 296(23):2832–2838.
46. Disanto G, Morahan JM, Ramagopalan SV: Multiple sclerosis: risk factors
and their interactions. CNS Neurol Disord Drug Targets 2012, 11(5):545–555.
doi:10.1186/1471-2377-13-60
Cite this article as: Golan et al.: Vitamin D supplementation for patients
with multiple sclerosis treated with interferon-beta: a randomized
controlled trial assessing the effect on flu-like symptoms and
immunomodulatory properties. BMC Neurology 2013 13:60.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
